Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down Syndrome
Open Access
- 19 April 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4), e61689
- https://doi.org/10.1371/journal.pone.0061689
Abstract
Down syndrome (DS) is a high-incidence genetic pathology characterized by severe impairment of cognitive functions, including declarative memory. Impairment of hippocampus-dependent long-term memory in DS appears to be related to anatomo-functional alterations of the hippocampal trisynaptic circuit formed by the dentate gyrus (DG) granule cells - CA3 pyramidal neurons - CA1 pyramidal neurons. No therapies exist to improve cognitive disability in individuals with DS. In previous studies we demonstrated that pharmacotherapy with fluoxetine restores neurogenesis, granule cell number and dendritic morphology in the DG of the Ts65Dn mouse model of DS. The goal of the current study was to establish whether treatment rescues the impairment of synaptic connectivity between the DG and CA3 that characterizes the trisomic condition. Euploid and Ts65Dn mice were treated with fluoxetine during the first two postnatal weeks and examined 45–60 days after treatment cessation. Untreated Ts65Dn mice had a hypotrophyc mossy fiber bundle, fewer synaptic contacts, fewer glutamatergic contacts, and fewer dendritic spines in the stratum lucidum of CA3, the terminal field of the granule cell projections. Electrophysiological recordings from CA3 pyramidal neurons showed that in Ts65Dn mice the frequency of both mEPSCs and mIPSCs was reduced, indicating an overall impairment of excitatory and inhibitory inputs to CA3 pyramidal neurons. In treated Ts65Dn mice all these aberrant features were fully normalized, indicating that fluoxetine can rescue functional connectivity between the DG and CA3. The positive effects of fluoxetine on the DG-CA3 system suggest that early treatment with this drug could be a suitable therapy, possibly usable in humans, to restore the physiology of the hippocampal networks and, hence, memory functions.Keywords
This publication has 42 references indexed in Scilit:
- Divergent Roles ofand Trk Receptors in BDNF's Effects on Dendritic Spine Density and MorphologyNeural Plasticity, 2012
- Restoration of Norepinephrine-Modulated Contextual Memory in a Mouse Model of Down SyndromeScience Translational Medicine, 2009
- Abnormal expression of synaptic proteins and neurotrophin-3 in the down syndrome mouse model Ts65DnNeuroscience, 2008
- The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndromeThe Journal of Physiology, 2007
- Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndromeExperimental Neurology, 2006
- Localization of Brain-Derived Neurotrophic Factor to Distinct Terminals of Mossy Fiber Axons Implies Regulation of Both Excitation and Feedforward Inhibition of CA3 Pyramidal CellsJournal of Neuroscience, 2004
- Ensemble Dynamics of Hippocampal Regions CA3 and CA1Neuron, 2004
- Hippocampal Long-Term Potentiation Suppressed by Increased Inhibition in the Ts65Dn Mouse, a Genetic Model of Down SyndromeJournal of Neuroscience, 2004
- Spatial memory deficits in segmental trisomic Ts65Dn miceBehavioural Brain Research, 1996
- Development of mossy fiber synapses in hippocampal slice cultureDevelopmental Brain Research, 1994